Treats hypertension. ANDA 77536, held by Chartwell Rx. Moexipril Hydrochloride.
As of Nov 16, 2026, ANDA 77536 (Moexipril Hydrochloride), held by Chartwell Rx, was first approved by FDA on Nov 30, 2006, with 0 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Moexipril hydrochloride tablets are indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride tablets, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride tablets do not have a similar risk (see WARNINGS ).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 30, 2006 | Original application | Approved | None posted |
| Moexipril Hydrochloride7.5MG · tablet;oral | Moexipril Hydrochloride | Rx |
| Moexipril Hydrochloride15MG · tablet;oral | Moexipril Hydrochloride | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters